First Report of a Phase II Prospective Study of Combination of Hyper-CVAD with Ponatinib in Frontline Therapy of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

BACKGROUND: The combination of chemotherapy with a tyrosine kinase inhibitor (TKI) is effective in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Ponatinib is a more potent BCR-ABL1 inhibitor and selectively suppresses the resistant T315I clones. We examined the effic...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Lancet Oncol
Main Authors: Jabbour, Elias, Kantarjian, Hagop, Ravandi, Farhad, Thomas, Deborah, Huang, Xuelin, Faderl, Stefan, Pemmaraju, Naveen, Daver, Naval, Garcia-Manero, Guillermo, Sasaki, Koji, Cortes, Jorge, Garris, Rebecca, Yin, C. Cameron, Khoury, Joseph D., Jorgensen, Jeffrey, Estrov, Zeev, Bohannan, Zachary, Konopleva, Marina, Kadia, Tapan, Jain, Nitin, DiNardo, Courtney, Wierda, William, Jeanis, Vicky, O’Brien, Susan
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4816046/
https://ncbi.nlm.nih.gov/pubmed/26432046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(15)00207-7
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki